Obara Keisuke, Yoshioka Kento, De Dios Regadera Montserrat, Matsuyama Yusuke, Yashiro Ayano, Miyokawa Mayumi, Iura Rumi, Tanaka Yoshio
Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University.
Biol Pharm Bull. 2023;46(2):309-319. doi: 10.1248/bpb.b22-00754.
We examined whether the α-adrenoceptor (AR), which shows low affinity (pA < 9) for prazosin (an α-AR antagonist) and high affinity (pA ≈ 10) for tamsulosin/silodosin (α-AR antagonists), is involved in phenylephrine-induced contractions in the guinea pig (GP) thoracic aorta (TA). Intracellular signaling induced by α-AR activation was also examined by focusing on Ca influx pathways. Tension changes of endothelium-denuded TAs were isometrically recorded and mRNA encoding α-ARs/Ca channels and their related molecules were measured using RT-quantitative PCR. Phenylephrine-induced contractions were competitively inhibited by prazosin/tamsulosin, and their pA value were calculated to be 8.53/9.74, respectively. These contractions were also inhibited by silodosin concentration-dependently. However, the inhibition was not competitive fashion with the apparent pA value being 9.48. In contrast, phenylephrine-induced contractions were not substantially suppressed by L-765314 (an α-AR antagonist), BMY 7378 (an α-AR antagonist), yohimbine, and idazoxan (α-AR antagonists). Phenylephrine-induced contractions were markedly inhibited by YM-254890 (a Gq protein inhibitor) or removal of extracellular Ca, and partially inhibited by verapamil (a voltage-dependent Ca channel (VDCC) inhibitor). The residual contractions in the presence of verapamil were slightly inhibited by LOE 908 (a receptor-operated Ca channel (ROCC) inhibitor) and strongly inhibited by SKF-96365 (a store-operated Ca channel (SOCC) and ROCC inhibitor). Among the mRNA encoding α-ARs/SOCC-related molecules, α-AR (Adra1a)/Orai3, Orai1, and Stim2 were abundant in this tissue. In conclusion, phenylephrine-induced contractions in the GP TA can be triggered by stimulation of Gq protein-coupled α-AR, followed by activation of SOCCs and VDCCs.
我们研究了对哌唑嗪(一种α-肾上腺素能受体拮抗剂)显示低亲和力(pA<9)而对坦索罗辛/西洛多辛(α-肾上腺素能受体拮抗剂)显示高亲和力(pA≈10)的α-肾上腺素能受体(AR)是否参与去甲肾上腺素诱导的豚鼠(GP)胸主动脉(TA)收缩。还通过关注钙内流途径研究了α-肾上腺素能受体激活诱导的细胞内信号传导。对等长记录去内皮TA的张力变化,并使用RT定量PCR测量编码α-肾上腺素能受体/钙通道及其相关分子的mRNA。去甲肾上腺素诱导的收缩被哌唑嗪/坦索罗辛竞争性抑制,其pA值分别计算为8.53/9.74。这些收缩也被西洛多辛浓度依赖性抑制。然而,抑制并非竞争性方式,表观pA值为9.48。相比之下,去甲肾上腺素诱导的收缩未被L-765314(一种α-肾上腺素能受体拮抗剂)、BMY 7378(一种α-肾上腺素能受体拮抗剂)、育亨宾和咪唑克生(α-肾上腺素能受体拮抗剂)显著抑制。去甲肾上腺素诱导的收缩被YM-254890(一种Gq蛋白抑制剂)或去除细胞外钙显著抑制,并被维拉帕米(一种电压依赖性钙通道(VDCC)抑制剂)部分抑制。维拉帕米存在时的残余收缩被LOE 908(一种受体操纵性钙通道(ROCC)抑制剂)轻微抑制,并被SKF-96365(一种储存操纵性钙通道(SOCC)和ROCC抑制剂)强烈抑制。在编码α-肾上腺素能受体/SOCC相关分子的mRNA中,α-肾上腺素能受体(Adra1a)/Orai3、Orai1和Stim2在该组织中丰富。总之,去甲肾上腺素诱导的GP TA收缩可由Gq蛋白偶联的α-肾上腺素能受体刺激引发,随后是SOCC和VDCC的激活。